A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study

por Nakai, Y, Isayama, H, Sasaki, T, Sasahira, N, Tsujino, T, Toda, N, Kogure, H, Matsubara, S, Ito, Y, Togawa, O, Arizumi, T, Hirano, K, Tada, M, Omata, M, Koike, K
Publicado 2012

Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy

por Hamada, T, Nakai, Y, Yasunaga, H, Isayama, H, Matsui, H, Takahara, N, Sasaki, T, Takagi, K, Watanabe, T, Yagioka, H, Kogure, H, Arizumi, T, Yamamoto, N, Ito, Y, Hirano, K, Tsujino, T, Tada, M, Koike, K
Publicado 2014

Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

por Nakai, Y, Isayama, H, Ijichi, H, Sasaki, T, Sasahira, N, Hirano, K, Kogure, H, Kawakubo, K, Yagioka, H, Yashima, Y, Mizuno, S, Yamamoto, K, Arizumi, T, Togawa, O, Matsubara, S, Tsujino, T, Tateishi, K, Tada, M, Omata, M, Koike, K
Publicado 2010

A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer(†)

por Ueno, M., Okusaka, T., Omuro, Y., Isayama, H., Fukutomi, A., Ikeda, M., Mizuno, N., Fukuzawa, K., Furukawa, M., Iguchi, H., Sugimori, K., Furuse, J., Shimada, K., Ioka, T., Nakamori, S., Baba, H., Komatsu, Y., Takeuchi, M., Hyodo, I., Boku, N.
Publicado 2016

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer

por Ohkawa, S, Okusaka, T, Isayama, H, Fukutomi, A, Yamaguchi, K, Ikeda, M, Funakoshi, A, Nagase, M, Hamamoto, Y, Nakamori, S, Tsuchiya, Y, Baba, H, Ishii, H, Omuro, Y, Sho, M, Matsumoto, S, Yamada, N, Yanagimoto, H, Unno, M, Ichikawa, Y, Takahashi, S, Watanabe, G, Wakabayashi, G, Egawa, N, Tsuda, M, Hosotani, R, Hamada, C, Hyodo, I
Publicado 2015